Top in endocrinology: Tirzepatide: shortage over, more effective than other obesity drugs
Click Here to Manage Email Alerts
The FDA announced that tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, has been removed from its drug shortage list.
On December 15, 2022, the FDA placed tirzepatide (Mounjaro/Zepbound, Eli Lilly) on its drug shortage list due to increased demand, which came less than 1 year after it received approval for the treatment diabetes.
The FDA based the removal on reassurance from Eli Lilly that the company can meet present and future demand for tirzepatide, confirming the availability of the drug and its manufacturing capacity.
It was the top story in endocrinology last week.
In another top story, researchers found that tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications without significantly higher adverse event risk.
Read these and more top stories in endocrinology below:
FDA removes tirzepatide from drug shortage list
Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced. Read more.
Tirzepatide, semaglutide more efficacious than other FDA-approved drugs for weight loss
Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications, with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity. Read more.
Generic version of injectable acromegaly treatment launches in US
A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release. Read more.
Q&A: Tips for navigating use of diabetes devices in schools
One of many challenges parents face when their child is diagnosed with diabetes is how the condition will be managed in school, particularly if the child is using a diabetes device. Healio spoke with Christine A. March, MD, MS, at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh, about the use of diabetes devices in schools and how school staff can educate themselves about a student’s device. Read more.
Decreases in BMI, HbA1c with diabetes drugs can lower cardiometabolic disease risks
Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported. Read more.